Latest Xenoport Inc (XNPT) Headlines XenoPort Earnings

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Latest Xenoport Inc (XNPT) Headlines

XenoPort Earnings In Retrospect: Down 0.3% in the Last 18 Days (XNPT)
Comtex SmarTrend(R) - Mon Mar 10, 7:55AM CDT
When XenoPort (NASDAQ:XNPT) reported earnings 18 days ago on February 20th, 2014, analysts, on average, expected the company to report a loss of $0.48 on sales of $3.8 million. XenoPort actually reported a loss of $0.40 per share on sales of $2.9 million, beating EPS estimates by $0.08 and missing revenue estimates by $0.9 million. Shares of XenoPort have slipped from $5.89 to $5.87, representing a loss of 0.3%, since the company reported earnings 18 days ago.

ESI to Present at Two March Investor Conferences
Business Wire - Tue Mar 04, 7:55AM CST
Electro Scientific Industries, Inc. (NASDAQ: ESIO), a leading supplier of innovative laser-based manufacturing solutions for the microtechnology industry, today announced it will be participating at two upcoming investor conferences, including:

XenoPort to Present at the Cowen and Company 34th Annual Health Care Conference
Business Wire - Mon Feb 24, 9:00AM CST
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via the World Wide Web to its presentation at the 2014 Cowen and Company 34th Annual Health Care Conference. The live presentation will occur at 7:40 a.m. Pacific Time (10:40 a.m. Eastern Time) on Wednesday, March 5, 2014. A replay of the presentation will also be available.

XenoPort's 4Q Loss Narrower-Than-Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 10:22AM CST
XenoPort's loss narrows in fourth quarter of 2013.

XenoPort Reports Fourth Quarter and Year-End 2013 Financial Results
Business Wire - Thu Feb 20, 3:05PM CST
XenoPort, Inc. (Nasdaq:XNPT) announced today its financial results for the fourth quarter and year ended December 31, 2013. Revenues for the fourth quarter were $2.9 million, compared to $0.5 million for the same period in 2012. Net loss for the fourth quarter was $19.1 million compared to net income of $3.0 million that resulted from a non-cash gain from XenoPort's litigation settlement with Glaxo Group Limited (GSK) in the fourth quarter of 2012. At December 31, 2013, XenoPort had cash and cash equivalents and short-term investments of $58.7 million.

UPS Honors New York Drivers for 25 Years of Safe Driving
Business Wire - Wed Feb 19, 9:00AM CST
UPS (NYSE:UPS) today announced 46 elite drivers from New York are among 1,519 newly inducted worldwide into the Circle of Honor, an honorary organization for UPS drivers who have achieved 25 or more years of accident-free driving.

Can a New Indication for Lyrica Help Results at Pfizer?
Eileen Rojas, The Motley Fool - Motley Fool - Tue Feb 18, 4:16PM CST
As revenue at Pfizer continues to decline, some relief may come in the form of a new indication for Lyrica, one of the company's top-selling drugs, to treat restless legs syndrome, or RLS. Lyrica was a top seller during 2013 Lyrica was a top...

XenoPort to Present at the RBC Capital Markets' Global Healthcare Conference
Business Wire - Tue Feb 18, 12:06PM CST
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via the World Wide Web to its presentation at the RBC Capital Markets' Global Healthcare Conference. The live presentation will occur at 11:35 a.m. Pacific Time (2:35 p.m. Eastern Time) on Tuesday, February 25, 2014. A replay of the presentation will also be available.

RLS/WED Survey of Patients' Spouses and Partners Reveals Their Concern of Disease-Related Burdens
Business Wire - Thu Feb 13, 7:30AM CST
The Willis-Ekbom Disease (WED) Foundation and XenoPort, Inc. (Nasdaq:XNPT) announced today the second phase of results from the "Patient Odyssey" survey, which reveals how Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED) may affect the lifestyles and emotional health of patients and their spouses/partners. The survey findings add another important layer of information to the current body of knowledge on RLS/WED. Moreover, the results from the survey showed that spouses/partners understand the impact of RLS/WED, as they are affected by the disease as well. The full survey results are available on the WED Foundation website (www.Willis-Ekbom.org).

XenoPort to Release Fourth Quarter and Year-End Financial Results on February 20, 2014
Business Wire - Wed Feb 12, 7:48PM CST
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will release its fourth quarter financial results on February 20, 2014 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day. A replay of the call will be available for one week following the event.

XenoPort Appoints Richard Kim, M.D., as Chief Medical Officer
Business Wire - Wed Jan 29, 7:30AM CST
XenoPort, Inc. (Nasdaq:XNPT) announced today that Richard Kim, M.D., has been appointed senior vice president, clinical development and medical affairs, and chief medical officer. Dr. Kim joined XenoPort in July 2013 as vice president of medical affairs, supporting XenoPort's launch of HORIZANT(R) (gabapentin enacarbil) Extended-Release Tablets. Dr. Kim has more than a decade of experience in both clinical development and medical affairs, most recently as vice president of clinical development and head of the multiple sclerosis therapeutic area at Elan Pharmaceuticals, Inc.

XenoPort Inc prices public offering at USD6.00 per share
M2 - Fri Jan 24, 4:07AM CST
Biopharmaceutical company XenoPort Inc (NasdaqGS :XNPT) said on Friday that it has priced a registered public offering of 12,000,000 shares of its common stock.

XenoPort Announces Pricing of Public Offering of Common Stock
Business Wire - Thu Jan 23, 10:00PM CST
XenoPort, Inc. (NASDAQ: XNPT) announced today the pricing of an underwritten registered public offering of 12,000,000 shares of its common stock at a price to the public of $6.00 per share. The size of the offering was increased from the 10,000,000 shares previously announced. XenoPort has also granted to the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of its common stock. All of the shares in the offering are being offered by XenoPort. The offering is expected to close on or about January 29, 2014, subject to customary closing conditions.

XenoPort Inc to offer 10m common shares in public offering
M2 - Wed Jan 22, 4:02AM CST
Biopharmaceutical company XenoPort Inc (NasdaqGS:XNPT) said on Tuesday that it proposes to offer and sell 10,000,000 shares of its common stock in an underwritten public offering.

XenoPort Announces Proposed Public Offering of Common Stock
Business Wire - Tue Jan 21, 5:00AM CST
XenoPort, Inc. (Nasdaq: XNPT) announced today that it intends to offer and sell 10,000,000 shares of its common stock, subject to market and other conditions, in an underwritten public offering. XenoPort also intends to grant the underwriters a 30-day option to purchase up to a maximum of 1,500,000 additional shares of common stock. All of the shares in the proposed public offering are to be sold by XenoPort.

Pipeline Update from XenoPort - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 16, 5:50PM CST
XenoPort provides update on its pipeline

Updates on Clinical Trial Enrollment, Product Development Updates, Clinical Collaboration, and Preliminary Sales Report - Research Report on Raptor, Synageva, XenoPort, Portola, and Zogenix
PR Newswire - Thu Jan 16, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Raptor Pharmaceutical Corp. (NASDAQ: RPTP), Synageva BioPharma Corporation (NASDAQ: GEVA), XenoPort, Inc. (NASDAQ: XNPT), Portola Pharmaceuticals, Inc. (NASDAQ: PTLA), and Zogenix, Inc. (NASDAQ: ZGNX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

XenoPort Provides Updates on XP23829 Development and HORIZANT Performance Highlights
Business Wire - Sun Jan 12, 11:59AM CST
XenoPort (NASDAQ:XNPT) today reported an update on XP23289 development, including feedback from the U.S. Food and Drug Administration (FDA) on the potential development plans, and XenoPort's progress on commercializing HORIZANT(R) (gabapentin enacarbil) Extended-Release Tablets.

Can the Rally in XenoPort, Inc. (XNPT) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 03, 8:01AM CST
Can the Rally in XenoPort, Inc. (XNPT) Shares Continue?

Clinton Group Calls on Xenoport to Hold Annual Elections for All Directors
PR Newswire - Mon Dec 16, 10:40AM CST
Clinton Group, Inc. ("Clinton Group"), one of the largest owners of Xenoport, Inc. (NASDAQ: XNPT) ("Xenoport"), sent a letter to the Lead Director of Xenoport, Dr. John G. Freund, following a recent meeting with Dr. Freund and Dennis Fenton, another independent director of Xenoport.

XenoPort Inc (XNPT) Stock Research Links

XNPT Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

SOCi's MCP Push Makes Context the Product Moat Bigger

Updated Category News Views 78

Software agents without decent business context are just eager interns with access to the keyboard. SOCi’s November 19, 2026 announcement gets at that unglamorous truth: the company has made its Model Context Protocol server generally available and says its context layer now connects with more than 140 integrations. It is not a flashy new chatbot stunt. It is a bid to...

Continue Reading
Palmer Holland Takes Natural Colors Across North America

Updated Category News Views 27

Natural food color sounds like a tidy little ingredient story until somebody tries to keep a blue beverage blue on a retail shelf. That is where Palmer Holland's new exclusive North American commercial arrangement with BOTANIKind gets interesting. This is not a flashy public-market transaction, and neither company has handed investors a revenue figure, volume target, or...

Continue Reading
PBS Holiday Special Bets on Apollo 8, Music and Unity

Updated Category News Views 47

A moon mission, a 360-voice choir, and Christmas television make an unusual bundle, but that is precisely why this year’s Tabernacle Choir special has some real staying power. Peace on Earth: Christmas with The Tabernacle Choir is not trying to chase whatever noisy trend is chewing up attention this week. It is building a 90-minute holiday event around Apollo 8,...

Continue Reading
M.O.L.I.F.E. Brings Community Inclusion Into Public View

Updated Category News Views 138

A food pantry can reveal more about inclusion than a polished mission statement ever will. M.O.L.I.F.E., Inc. is set to be featured in an educational segment of All Access with Andy Garcia, and the useful part of this story is not the celebrity-host packaging. It is the organization’s insistence that employment, independent living, day programming, residential support,...

Continue Reading
Mace Consult Bets on Sawaya for Americas Expansion

Updated Category News Views 120

Concrete, tunnel bores, and data-center campuses rarely wait politely for a leadership transition. Mace Consult has named Mario Sawaya president of its Americas business, and the hire reads less like ceremonial executive shuffling than a deliberate move toward the thickest part of the capital-spending map. Sawaya brings more than 20 years of experience leading...

Continue Reading
Art Limitless Jury Puts SDG 12 and Art Into Clear Focus

Updated Category News Views 30

A paint pigment, a discarded object, and a serious climate question have landed in the same room. BE OPEN Art’s 2026 Art Limitless competition is aimed at SDG 12, the United Nations goal centered on responsible production and consumption. That may sound like institutional language built for conference folders, but the underlying issue is plain enough: society cannot...

Continue Reading
UTI Faces Fresh Scrutiny After Its Earnings Guidance Miss

Updated Category News Views 74

A Guidance Gap That Cannot Be Shrugged Off A $0.20-per-share hole is a nasty thing to find after management said it could see the road ahead. Universal Technical Institute reported fiscal 2026 diluted earnings per share of $0.60, below the $0.71 to $0.80 range it reaffirmed on May 6. That is at least $0.11 under the low end and roughly 21% below the midpoint. For...

Continue Reading
PG&E's $456 Million Interim Hike Faces a New Test Soon

Updated Category News Views 112

A utility can call a charge interim, but households still see the bill arrive in full. That is why the California Public Utilities Commission's unanimous approval of $456 million in interim rate recovery for Pacific Gas & Electric has landed with such rotten timing. The money is set to begin flowing from customers on January 1, 2027, while major questions about PG&E's...

Continue Reading
Cineverse Sets Wolf Creek Return for March 19, 2027

Updated Category News Views 121

A sunburned serial killer is heading back to theaters, and Cineverse has finally put a date on it: March 19, 2027. WOLF CRE3K, formerly called Wolf Creek: Legacy, brings John Jarratt back as Mick Taylor for the third film in the Australian horror franchise. For NASDAQ:CNVS investors, this is not the kind of announcement that lets anyone pencil in revenue with a straight...

Continue Reading
Corner Bakery Bets on Holiday Catering Convenience

Updated Category News Views 101

A $50 carrot on a $350 catering tab tells you exactly where Corner Bakery sees the holiday battlefield: not in one lonely cookie sale, but in the larger group order that can make a restaurant’s day. The chain is pushing holiday catering through November and December, pairing that discount with bakery trays, meals for groups and a promise to handle delivery setup. It is...

Continue Reading

Top 5 Most Recently Viewed Articles

Mobile Homes Market Grows to $16.62B by 2031

Updated Category News Views 24

Affordable Housing Fuels Mobile Homes Market When the traditional real estate market is out of reach, what's the average Joe supposed to do? Enter the mobile home market, which is expected to leap from $11.87 billion in 2026 to a hefty $16.62 billion by 2031. That's a compound annual growth rate (CAGR) of 6.96%—not too shabby for a sector often ignored by the mainstream...

Continue Reading
KinderCare Investors Face Legal Challenges Over IPO Misrepresentation

Updated Category News Views 213

Legal Action Against KinderCare Learning Companies A securities class action lawsuit has been initiated against KinderCare Learning Companies, Inc. (NYSE: KLC) and its executives. This lawsuit centers on allegations that the company misrepresented its activities and safety records during its Initial Public Offering (IPO) in October 2024. Investors who acquired KLC common...

Continue Reading
Intec Pharma Ltd's Stock Sees Decline: A Deeper Analysis

Updated Category News Views 204

Intec Pharma Ltd Faces a Rocky Road Intec Pharma Ltd (NASDAQ: INDP) is knee-deep in trouble, with its stock diving to a brutal 52-week low of $1.20. This stark drop of 56.12% over the past year paints a dismal picture for investors scoping out this biotech player. It’s no surprise that all eyes are on INDP as it struggles to navigate these choppy waters and rebuild its...

Continue Reading
Sol Rei Wine Shines at San Francisco Wine Competition

Updated Category News Views 190

Celebrating Excellence at the San Francisco Wine Competition In an impressive display of craftsmanship and quality, Sol Rei Wine has recently achieved remarkable accolades at the esteemed San Francisco Wine Competition. This boutique, women-owned wine brand has won both Double Gold and Gold medals for their exquisite offerings: the Sol Rei Syrah and the Sol Rei Private...

Continue Reading
Insight Molecular Diagnostics Gears Up for Exciting 2026 Launch

Updated Category News Views 260

Exciting Progress Ahead for Insight Molecular Diagnostics Inc. Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) is taking significant strides towards launching its innovative GraftAssureDx™ test in 2026. With anticipation building within the organization and among stakeholders, the company is preparing to submit its application for FDA approval by the year's end. This...

Continue Reading